<p>The Effectiveness Of Radial Extracorporeal Shock Wave Therapy In Patients With Chronic Low Back Pain: A Prospective, Randomized, Single-Blinded Pilot Study</p>

Background: Extracorporeal Shock Wave Therapy (ESWT) has become a popular tool to treat musculoskeletal disorders and chronic low back pain. Aim of the study: To review the current scientific literature and assess the utility of ESWT in treating chronic low back pain. Methods: This systematic review was conducted from November 2019 to January 2020. Its purpose was to determine what the effectiveness is of the various forms of ESWT for the treatment of chronic low back pain. The critical review of the literature on the use of ESWT in chronic low back was made using the scientifically recognized medical databases PubMed, MEDLINE, Physiotherapy Evidence Database (PEDro) and Web of Science Core Collection. There was no restriction by date. Exclusion criteria were experimental, in vitro, animal, review, case reports, non-randomized clinical trials or studies with healthy participants. All articles written in languages other than English have also been excluded. Results: Six studies were included in the final analysis. According to the applied PEDro classification, the average scoring for the studies was 4.83, which indicates overall low quality of the presented reports. However, this result appeared closer to the moderate (acceptable) quality range (6-8 points) than to the unacceptable range (0-2 points). Conclusion: Based on the findings in the analyzed articles, ESWT promises to be an efficient and useful procedure in chronic low back pain treatment. Unfortunately, the level of evidence is relatively weak because there are a limited number of published studies related to ESWT and the final score in the PEDro classification was low. Together, these results indicate the need for further high quality randomized clinical trials.

Download Full-text

The Efficacy of Extracorporeal Shock Wave Therapy in the Treatment of Myofascial Low Back Pain Syndrome

TRAUMA ◽

10.22141/1608-1706.1.17.2016.74227 ◽

2016 ◽

Vol 17 (1) ◽

pp. 121

Author(s):

I.M. Voloshyna ◽

V.H. Deineha ◽

V.I. Kryvenko ◽

A.V. Onishchenko ◽

D.L. Maliarchuk

Keyword(s):

Shock Wave ◽

Low Back Pain ◽

Back Pain ◽

Pain Syndrome ◽

Extracorporeal Shock Wave Therapy ◽

Low Back ◽

Shock Wave Therapy ◽

Extracorporeal Shock Wave

Download Full-text

Shock wave therapy for chronic low back pain

http://isrctn.com/ ◽

10.1186/isrctn13785224 ◽

2019 ◽

Author(s):

Katarzyna Rajfur ◽

Jakub Taradaj

Keyword(s):

Shock Wave ◽

Low Back Pain ◽

Back Pain ◽

Chronic Low Back Pain ◽

Low Back ◽

Shock Wave Therapy

Download Full-text

Efficacy and safety of treating chronic nonspecific low back pain with radial extracorporeal shock wave therapy (rESWT), rESWT combined with celecoxib and eperisone (C+E) or C+E alone: a prospective, randomized trial

10.1101/2020.11.28.20240119 ◽

2020 ◽

Author(s):

Xuejiao Guo ◽

Lin Li ◽

Zhe Yan ◽

Yunze Li ◽

Zhiyou Peng ◽

...

Keyword(s):

Shock Wave ◽

Low Back Pain ◽

Back Pain ◽

Rating Scale ◽

Numerical Rating Scale ◽

Controlled Trial ◽

Low Back ◽

Shock Wave Therapy ◽

Level Of Evidence ◽

Extracorporeal Shock Wave

AbstractBackgroundTo investigate whether respectively radial extracoporeal shock wave therapy (rESWT) or a combination of rESWT, Celecoxib and Eperisone (rESWT+C+E) are superior in reducing pain in subjects with chronic nonspecific low back pain (cnsLBP) compared to C+E alone (a standard treatment of this condition in China).Methods140 subjects with cnsLBP were randomly allocated to rESWT (n=47), rESWT+C+E (n=45) or C+E alone (n=48) for four weeks. Outcome was evaluated using the Pain Self-Efficacy Questionnaire (PSEQ), Numerical Rating Scale (NRS), Oswestry Low Back Pain Disability Questionnaire and Patient Health Questionnaire 9, collected at one week (W1), W2, W3, W4 and W12 after beginning of the therapy.ResultsAll scores showed a statistically significant improvement over time. The PSEQ and NRS scores showed a significant Time × Treatment effect. Subjects treated with rESWT had significantly lower mean NRS values than subjects treated with rESWT+C+E at W1 and W3, as well as than subjects treated with C+E alone at W3 and W4. No severe adverse events were observed.ConclusionrESWT may be superior to respectively rESWT+C+E or C+E alone in reducing pain in subjects with cnsLBP. Level of Evidence: Level I, prospective, randomized, active-controlled trial.

Download Full-text

Efficacy and safety of treating chronic nonspecific low back pain with radial extracorporeal shock wave therapy (rESWT), rESWT combined with celecoxib and eperisone (C + E) or C + E alone: a prospective, randomized trial

Journal of Orthopaedic Surgery and Research ◽

10.1186/s13018-021-02848-x ◽

2021 ◽

Vol 16 (1) ◽

Author(s):

Xuejiao Guo ◽

Lin Li ◽

Zhe Yan ◽

Yunze Li ◽

Zhiyou Peng ◽

...

Keyword(s):

Shock Wave ◽

Low Back Pain ◽

Back Pain ◽

Rating Scale ◽

Controlled Trial ◽

Low Back ◽

Shock Wave Therapy ◽

Level Of Evidence ◽

Extracorporeal Shock Wave ◽

Level I

Abstract Background To investigate whether respectively radial extracoporeal shock wave therapy (rESWT) or a combination of rESWT, celecoxib and eperisone (rESWT + C + E) are superior in reducing pain in patients with chronic nonspecific low back pain (cnsLBP) compared to C + E alone (a standard treatment of this condition in China). Methods 140 patients with cnsLBP were randomly allocated to rESWT (n = 47), rESWT + C + E (n = 45) or C + E alone (n = 48) for four weeks between November 2017 and March 2019. Outcome was evaluated using the Pain Self-Efficacy Questionnaire (PSEQ), Numerical Rating Scale (NRS), Oswestry Low Back Pain Disability Questionnaire and Patient Health Questionnaire 9, collected at baseline as well as one week (W1), W2, W3, W4 and W12 after baseline. Results All scores showed a statistically significant improvement over time. The PSEQ and NRS scores showed a significant Time × Treatment effect. Patients treated with rESWT had significantly lower mean NRS values than patients treated with rESWT + C + E at W1 and W3, as well as than patients treated with C + E alone at W3 and W4. No severe adverse events were observed. Conclusions rESWT may not be inferior to respectively rESWT + C + E or C + E alone in reducing pain in patients with cnsLBP. Level of Evidence: Level I, prospective, randomized, active-controlled trial. Trial registration: Clinicaltrials.gov Identifier NCT03337607. Registered November 09, 2017, https://www.clinicaltrials.gov/ct2/show/NCT03337607. Level of evidence Level I; prospective, randomized, controlled trial.

Download Full-text